We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Intercept (ICPT) Earnings and Sales Miss Estimates in Q3
Read MoreHide Full Article
Intercept Pharmaceuticals, Inc.’s shares declined 2% after it reported wider-than-expected loss for the third quarter of 2019 and revenues fell short of expectations as well
Shares of the company have lost 26.1% in the year so far against the industry’s growth of 0.9%.
The company incurred a loss of $2.59 per share in the third quarter, wider than the Zacks Consensus Estimate of a loss of $2.35 and the year-ago quarter’s loss of $2.18.
Quarterly revenues were $61.9 million, up from $46.9 million in the year-ago quarter. However, revenues missed the Zacks Consensus Estimate of $64 million.
Quarter in Detail
Lead drug Ocaliva (obeticholic acid or OCA) reported $61.5 million in sales, up from $46.6 million in the year-earlier quarter. Net sales in the United States came in at $45.2 million, while ex-U.S. Ocaliva net sales summed $16.3 million.
During the third quarter, the company submitted a new drug application (NDA) seeking accelerated approval of OCA for non-alcoholic steatohepatitis (“NASH”) in the United States. The marketing authorization application (“MAA”) submission for the same is planned for fourth quarter of 2019
Research and development expenses increased 25.7% year over year to $60.2 million, primarily driven by higher NASH development program expenses and costs associated with the preparation of the NASH NDA submission.
2019 Outlook
For 2019, the company raised its net sales guidance for Ocaliva and expects it to be in the range of $245 million and $250 million up from the previous range of $235 million and $245 million. Intercept narrowed its adjusted operating expenses guidance range to $480- $500 million, from $470 -$500 million.
Intercept Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
ASLAN’s loss per share estimates have narrowed from 79 cents to 72 cents fr 2019 and from 83 cents to 71 cents for 2020 in the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters by 24.65% on average.
Acorda’s loss per share estimates have narrowed from $2.94 to $2.18 for 2019 and from $3.74 to $1.95 for 2020 in the past 60 days. The company delivered a positive earnings surprise in the trailing four quarters by 68.80% on average
AVEO’s estimates have gone up from a loss of 6 cents to a profit of 1 cent. The company delivered a positive earnings surprise in three of the trailing four quarters by 28.34% on average..
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.5% per year. These 7 were selected because of their superior potential for immediate breakout.
Image: Bigstock
Intercept (ICPT) Earnings and Sales Miss Estimates in Q3
Intercept Pharmaceuticals, Inc.’s shares declined 2% after it reported wider-than-expected loss for the third quarter of 2019 and revenues fell short of expectations as well
Shares of the company have lost 26.1% in the year so far against the industry’s growth of 0.9%.
The company incurred a loss of $2.59 per share in the third quarter, wider than the Zacks Consensus Estimate of a loss of $2.35 and the year-ago quarter’s loss of $2.18.
Quarterly revenues were $61.9 million, up from $46.9 million in the year-ago quarter. However, revenues missed the Zacks Consensus Estimate of $64 million.
Quarter in Detail
Lead drug Ocaliva (obeticholic acid or OCA) reported $61.5 million in sales, up from $46.6 million in the year-earlier quarter. Net sales in the United States came in at $45.2 million, while ex-U.S. Ocaliva net sales summed $16.3 million.
During the third quarter, the company submitted a new drug application (NDA) seeking accelerated approval of OCA for non-alcoholic steatohepatitis (“NASH”) in the United States. The marketing authorization application (“MAA”) submission for the same is planned for fourth quarter of 2019
Research and development expenses increased 25.7% year over year to $60.2 million, primarily driven by higher NASH development program expenses and costs associated with the preparation of the NASH NDA submission.
2019 Outlook
For 2019, the company raised its net sales guidance for Ocaliva and expects it to be in the range of $245 million and $250 million up from the previous range of $235 million and $245 million. Intercept narrowed its adjusted operating expenses guidance range to $480- $500 million, from $470 -$500 million.
Intercept Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Intercept Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Intercept Pharmaceuticals, Inc. Quote
Our Take
Intercept reported a wider than expected loss and missed sales estimates in the third-quarter of 2019.
Nevertheless, the company’s efforts todevelop OCA for NASH is encouraging given the market potential.
Zacks Rank & Stocks to Consider
Intercept currently carries a Zacks Rank #4 (Sell).
A few better-ranked stock in the biotech sector are ASLAN Pharmaceuticals Ltd. (ASLN - Free Report) Acorda Therapeutics Inc. and AVEO Pharmaceuticals Inc. both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
ASLAN’s loss per share estimates have narrowed from 79 cents to 72 cents fr 2019 and from 83 cents to 71 cents for 2020 in the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters by 24.65% on average.
Acorda’s loss per share estimates have narrowed from $2.94 to $2.18 for 2019 and from $3.74 to $1.95 for 2020 in the past 60 days. The company delivered a positive earnings surprise in the trailing four quarters by 68.80% on average
AVEO’s estimates have gone up from a loss of 6 cents to a profit of 1 cent. The company delivered a positive earnings surprise in three of the trailing four quarters by 28.34% on average..
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.5% per year. These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>